IRIDEX CORP (IRIX) Stock Fundamental Analysis

NASDAQ:IRIX • US4626841013

1.38 USD
0 (0%)
Last: Feb 13, 2026, 08:17 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall IRIX gets a fundamental rating of 2 out of 10. We evaluated IRIX against 185 industry peers in the Health Care Equipment & Supplies industry. IRIX has a bad profitability rating. Also its financial health evaluation is rather negative. IRIX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year IRIX has reported negative net income.
  • In the past year IRIX has reported a negative cash flow from operations.
  • IRIX had negative earnings in each of the past 5 years.
  • In the past 5 years IRIX reported 4 times negative operating cash flow.
IRIX Yearly Net Income VS EBIT VS OCF VS FCFIRIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

1.2 Ratios

  • IRIX has a Return On Assets (-17.94%) which is comparable to the rest of the industry.
  • IRIX has a Return On Equity of -108.67%. This is in the lower half of the industry: IRIX underperforms 62.70% of its industry peers.
Industry RankSector Rank
ROA -17.94%
ROE -108.67%
ROIC N/A
ROA(3y)-25.41%
ROA(5y)-21.92%
ROE(3y)-189.74%
ROE(5y)-125.62%
ROIC(3y)N/A
ROIC(5y)N/A
IRIX Yearly ROA, ROE, ROICIRIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • The Gross Margin of IRIX (38.18%) is worse than 69.19% of its industry peers.
  • In the last couple of years the Gross Margin of IRIX has remained more or less at the same level.
  • IRIX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 38.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.83%
GM growth 5Y-0.6%
IRIX Yearly Profit, Operating, Gross MarginsIRIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • IRIX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for IRIX has been increased compared to 1 year ago.
  • The number of shares outstanding for IRIX has been increased compared to 5 years ago.
  • The debt/assets ratio for IRIX is higher compared to a year ago.
IRIX Yearly Shares OutstandingIRIX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
IRIX Yearly Total Debt VS Total AssetsIRIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

  • Based on the Altman-Z score of -2.03, we must say that IRIX is in the distress zone and has some risk of bankruptcy.
  • IRIX has a Altman-Z score (-2.03) which is in line with its industry peers.
  • IRIX has a Debt/Equity ratio of 0.79. This is a neutral value indicating IRIX is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.79, IRIX is not doing good in the industry: 70.81% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Altman-Z -2.03
ROIC/WACCN/A
WACC9.91%
IRIX Yearly LT Debt VS Equity VS FCFIRIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 1.94 indicates that IRIX should not have too much problems paying its short term obligations.
  • IRIX has a Current ratio of 1.94. This is in the lower half of the industry: IRIX underperforms 62.16% of its industry peers.
  • IRIX has a Quick Ratio of 1.35. This is a normal value and indicates that IRIX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of IRIX (1.35) is worse than 62.16% of its industry peers.
Industry RankSector Rank
Current Ratio 1.94
Quick Ratio 1.35
IRIX Yearly Current Assets VS Current LiabilitesIRIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • IRIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.22%, which is quite impressive.
  • IRIX shows a small growth in Revenue. In the last year, the Revenue has grown by 4.58%.
  • The Revenue has been growing slightly by 2.29% on average over the past years.
EPS 1Y (TTM)55.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)4.58%
Revenue growth 3Y-3.35%
Revenue growth 5Y2.29%
Sales Q2Q%7.77%

3.2 Future

  • Based on estimates for the next years, IRIX will show a very strong growth in Earnings Per Share. The EPS will grow by 21.63% on average per year.
  • Based on estimates for the next years, IRIX will show a small growth in Revenue. The Revenue will grow by 6.42% on average per year.
EPS Next Y49%
EPS Next 2Y36.67%
EPS Next 3Y27.94%
EPS Next 5Y21.63%
Revenue Next Year5.44%
Revenue Next 2Y6.78%
Revenue Next 3Y6.62%
Revenue Next 5Y6.42%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IRIX Yearly Revenue VS EstimatesIRIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 20M 40M 60M
IRIX Yearly EPS VS EstimatesIRIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IRIX. In the last year negative earnings were reported.
  • Also next year IRIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IRIX Price Earnings VS Forward Price EarningsIRIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IRIX Per share dataIRIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • A more expensive valuation may be justified as IRIX's earnings are expected to grow with 27.94% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.67%
EPS Next 3Y27.94%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IRIX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IRIDEX CORP

NASDAQ:IRIX (2/13/2026, 8:17:55 PM)

1.38

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-11
Earnings (Next)03-05
Inst Owners16.49%
Inst Owner Change9.94%
Ins Owners5.47%
Ins Owner Change2.8%
Market Cap23.72M
Revenue(TTM)50.65M
Net Income(TTM)-5.09M
Analysts43.33
Price TargetN/A
Short Float %1.15%
Short Ratio1.33
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.21%
Min EPS beat(2)-47.06%
Max EPS beat(2)34.64%
EPS beat(4)3
Avg EPS beat(4)1.96%
Min EPS beat(4)-47.06%
Max EPS beat(4)34.64%
EPS beat(8)3
Avg EPS beat(8)-47.26%
EPS beat(12)5
Avg EPS beat(12)-32.04%
EPS beat(16)8
Avg EPS beat(16)-23.31%
Revenue beat(2)1
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-6.6%
Max Revenue beat(2)0.79%
Revenue beat(4)1
Avg Revenue beat(4)-3.96%
Min Revenue beat(4)-6.6%
Max Revenue beat(4)0.79%
Revenue beat(8)1
Avg Revenue beat(8)-6.28%
Revenue beat(12)1
Avg Revenue beat(12)-5.95%
Revenue beat(16)3
Avg Revenue beat(16)-4.46%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.47
P/FCF N/A
P/OCF N/A
P/B 5.07
P/tB 8.95
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)-0.23
FCFYN/A
OCF(TTM)-0.23
OCFYN/A
SpS2.95
BVpS0.27
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.94%
ROE -108.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 38.18%
FCFM N/A
ROA(3y)-25.41%
ROA(5y)-21.92%
ROE(3y)-189.74%
ROE(5y)-125.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.83%
GM growth 5Y-0.6%
F-Score4
Asset Turnover1.79
Health
Industry RankSector Rank
Debt/Equity 0.79
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.07%
Cap/Sales 0.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.94
Quick Ratio 1.35
Altman-Z -2.03
F-Score4
WACC9.91%
ROIC/WACCN/A
Cap/Depr(3y)23.78%
Cap/Depr(5y)23.52%
Cap/Sales(3y)0.25%
Cap/Sales(5y)0.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y49%
EPS Next 2Y36.67%
EPS Next 3Y27.94%
EPS Next 5Y21.63%
Revenue 1Y (TTM)4.58%
Revenue growth 3Y-3.35%
Revenue growth 5Y2.29%
Sales Q2Q%7.77%
Revenue Next Year5.44%
Revenue Next 2Y6.78%
Revenue Next 3Y6.62%
Revenue Next 5Y6.42%
EBIT growth 1Y71.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year69.51%
EBIT Next 3Y35.48%
EBIT Next 5Y27.2%
FCF growth 1Y47.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.41%
OCF growth 3YN/A
OCF growth 5YN/A

IRIDEX CORP / IRIX FAQ

Can you provide the ChartMill fundamental rating for IRIDEX CORP?

ChartMill assigns a fundamental rating of 2 / 10 to IRIX.


Can you provide the valuation status for IRIDEX CORP?

ChartMill assigns a valuation rating of 1 / 10 to IRIDEX CORP (IRIX). This can be considered as Overvalued.


How profitable is IRIDEX CORP (IRIX) stock?

IRIDEX CORP (IRIX) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for IRIX stock?

The Earnings per Share (EPS) of IRIDEX CORP (IRIX) is expected to grow by 49% in the next year.